Search
Search Results
-
Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease
Pioglitazone ameliorates liver dysfunction in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD); however, its efficacy in...
-
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
BackgroundC3-glomerulopathy (C3G) is a rare pediatric kidney disease characterised by dysregulation of the alternative complement pathway, with...
-
Inhibition of PI3K Signaling Intensified the Antileukemic Effects of Pioglitazone: New Insight into the Application of PPARγ Stimulators in Acute Lymphoblastic Leukemia
Over the past two decades, molecular targeted therapy has revolutionized the landscape of cancer treatment due to lower side effects as well as...
-
Supplemental Pioglitazone to Patients of CML with Suboptimal TKI Response: A Pragmatic Pilot Study
Tyrosine kinase inhibitors (TKIs) have improved outcomes of chronic myeloid leukemia (CML). However, 20–30% of patients require second-line TKIs...
-
Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial
AimElevated fibroblast growth factor-23 (FGF23) is an established marker of cardiovascular disease among patients with type 2 diabetes (T2DM) and...
-
Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
BackgroundNonalcoholic fatty liver disease (NAFLD) is a complex metabolic disorder that increases the risk for cardiovascular disease in patients...
-
Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation
BackgroundRenal ischemia-reperfusion injury (RIRI) is a critical phenomenon that compromises renal function and is the most serious health concern...
-
Adolescent polycystic ovary syndrome without obesity: HOTAIR rs1443512 genotype relates to fat mass and to the redistribution of fat mass on low-dose pioglitazone
IntroductionAdolescent polycystic ovary syndrome (PCOS) is characterized by androgen excess and oligo-amenorrhea, and often results from ectopic...
-
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome
BackgroundNephrotic syndrome (NS) is a common pediatric kidney disease, yet current treatments for complicated NS are only partially effective and...
-
Method operable design region for robust RP-HPLC analysis of pioglitazone hydrochloride and teneligliptin hydrobromide hydrate: incorporating hybrid principles of white analytical chemistry and design of experiments
BackgroundA combination of pioglitazone hydrochloride with teneligliptin hydrobromide hydrate is used to treat type-2 diabetes. Several...
-
A meta-analysis of randomized clinical trials on the effect of metformin vs. pioglitazone monotherapy on plasma adiponectin levels among patients with diabetes mellitus
BackgroundLimited and contradicting findings were observed on the effects of both metformin (MET) and pioglitazone (PIO) on adiponectin (ADP) levels....
-
Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
BackgroundDue to the progressive decline in β-cell function, it is often necessary to utilize multiple agents with complementary mechanisms of action...
-
Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells
BackgroundDespite antitumor properties, chemotherapy medication can create conditions in tumor cells that work in favor of the tumor. Doxorubicin,...
-
Metformin versus metformin plus pioglitazone on gonadal and metabolic profiles in normal-weight women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial
ObjectiveTo investigate the effects of metformin (MET) monotherapy and pioglitazone plus MET (PIOMET) therapy on gonadal and metabolic profiles in...
-
Metabolic shift of chronic myeloid leukemia patients under imatinib–pioglitazone regimen and discontinuation
AbstractThe Estudo de Descontinuação de Imatinibe após Pioglitazona (EDI-PIO) is a single-center, longitudinal, prospective, phase 2, non-randomized,...
